NEUVOGEN is pioneering the next generation of cancer vaccines.
Cancer vaccines have shown promise — but they have not yet delivered on their full potential. Too often, they are limited in scope, costly to produce, or too complex to integrate into real-world care.
NEUVOGEN’s breakthrough approach combines scientific rigor with practical accessibility. Our off-the-shelf cancer vaccines are designed to:
- Deliver a broader immune response
- Reach more patients, earlier in their care journey
- Integrate into routine clinical settings
Patients deserve better.
At NEUVOGEN, we believe cancer vaccines can and must do more and for more people.
What Makes NEUVOGEN Different?
Unprecedented Immune Breadth
Our proprietary activation technology drives T cell responses against a wide and diverse set of tumor antigens — far beyond the narrow targets of traditional vaccines. This breadth is designed to target the primary tumor, micro-metastases, and metastases by activating the patient’s own immune system.
Built for Real-World Use
NEUVOGEN vaccines are off-the-shelf, intradermally administered, and ready to be used in any clinical setting — no patient-specific customization needed. They’re simple to deliver, scalable to manufacture, and easier to incorporate into the standard of care.
Broader Access for Patients
Because of our efficient manufacturing and simplified logistics, our vaccines are designed to dramatically lower the cost of goods, expanding access to patients who might otherwise be left behind.
How Our Platform Works
1. Rigorous Cell Line Selection
We apply advanced bioinformatics and screening to select cell lines that reflect the full complexity and diversity of each type of cancer.
2. Proprietary Genetic Engineering
Each selected line is enhanced to express a broad range of cancer antigens and modified using NEUVOGEN’s activation technology to amplify immune stimulation.
3. Straightforward Manufacturing
Engineered cell lines are expanded, irradiated, and formulated into two master vaccine cocktails — stable, scalable, and ready for clinical use.
Data in Focus: AACR 2025
In April 2025, we presented new findings at the American Association for Cancer Research (AACR) annual meeting.
Our poster, “An Optimized Off-the-Shelf Whole Tumor Cell Vaccine Activates T Cells That Recognize a Diverse Antigen Repertoire…”, highlights robust immune activation and broad T cell responses in patients with NSCLC.
Why Breadth Matters
Tumors are not uniform — they evolve, adapt, and evade therapies. That’s why immunogenic breadth is critical.
Our vaccines are designed to generate polyfunctional T cells targeting a wide range of antigens. This increases the chance of eliminating cancer at all stages and reduces the risk of relapse, even as the tumor mutates.
We believe NEUVOGEN’s approach has the potential to significantly improve survival outcomes — and lower the need for expensive late-stage treatments.
Vaccines Designed for Every Stage of Cancer Care
NEUVOGEN is building the next generation of cancer immunotherapies — engineered from the ground up to work better, reach more people, and integrate seamlessly into standard of care. Cancer vaccines are most effective in early-stage settings, but NEUVOGEN’s platform is also built to complement other therapies in later-stage disease.
As tumors metastasize there is a shift in gene expression and they develop more complex microenvironments. Our broad-spectrum immune activation may provide a crucial foundation for combination strategies — giving physicians more tools, and patients more hope.
We believe a future where cancer vaccines are accessible, effective, and life-extending is not just possible — it’s within reach.
For more information about our Pipeline.